Update in diffuse parenchymal lung disease 2012

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 9, 2013, Pages 920-925

  Selman, Moisés ^a   Pardo, Annie ^b  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; BIOLOGICAL MARKER; CD151 ANTIGEN; CRYOPYRIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INFLAMMASOME; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MATRILYSIN; MATRIX METALLOPROTEINASE 19; NOTCH4 RECEPTOR; PLATELET DERIVED GROWTH FACTOR AA; PREDNISONE; PROSTAGLANDIN E2; PROTEIN S 100; PROTEIN S100A12; REACTIVE OXYGEN METABOLITE; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; TETRASPANIN; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; WARFARIN;

ALLERGIC PNEUMONITIS; ARTICLE; CELL COMMUNICATION; COUGHING; DIFFERENTIAL DIAGNOSIS; DIFFUSE PARENCHYMAL LUNG DISEASE; DISEASE COURSE; EPIGENETICS; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS EPITHELIUM; LUNG DISEASE; LUNG FIBROBLAST; LUNG LAVAGE; LUNG SARCOIDOSIS; LYMPHANGIOLEIOMYOMATOSIS; NONHUMAN; PATHOGENESIS; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

BIOMEDICAL RESEARCH; DISEASE PROGRESSION; HUMANS; LUNG DISEASES, INTERSTITIAL;

EID: 84877151972     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201302-0331UP     Document Type: Article

References (57)

1. Meyer KC, Raghu G, Baughman R.P., Brown KK, Costabel U, du Bois RM, Drent M, Haslam PL, Kim DS, Nagai S, et al.; American Thoracic Society Committee on BAL in Interstitial Lung Disease. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012; 185:1004-1014.
2. Noth I, Anstrom KJ, Calvert S.B., de Andrade J, Flaherty KR, Glazer C, Kaner R.J., Olman MA; Idiopathic Pulmonary Fibrosis Clinical Research Network. (IPFnet). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186:88-95.
3. Müller-Quernheim J., Wells A. Evidence-based recommendations in idiopathic pulmonary fibrosis: a year is a long time in interstitial lung disease. Am J Respir Crit Care Med 2012; 186:5-7.
4. Idiopathic Pulmonary Fibrosis Clinical Research Network. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366:1968-1977.
5. Horton MR, Santopietro V, Mathew L., Horton KM, Polito AJ, Liu MC, Danoff SK, Lechtzin N. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 2012; 157:398-406.
6. Raghu G, Collard HR, Anstrom K.J., Flaherty KR, Fleming TR, King TE Jr, Martinez FJ, Brown KK. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012; 185:1044-1048.
7. du Bois R.M., Nathan SD, Richeldi L, Schwarz M.I., Noble PW Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med 2012; 186:712-715.
8. du Bois R.M., Weycker D, Albera C., Bradford WZ, Costabel U, Kartashov A, King TE Jr, Lancaster L, Noble PW, Sahn SA, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184:1382-1389.
9. Wells AU, Behr J, Costabel U., Cottin V, Poletti V, Richeldi L; European IPF Consensus Group. Hot of the breath: mortality as a primary endpoint in IPF treatment trials: the best is the enemy of the good. Thorax 2012; 67:938-940.
10. Vancheri C, du Bois RM. A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer. Eur Respir J 2013; 41:262-269.
11. Olson AL, Swigris JJ, Brown KK Clinical trials and tribulations-lessons from pulmonary fibrosis. QJM 2012; 105:1043-1047.
12. du Bois R.M., Weycker D, Albera C., Bradford WZ, Costabel U, Kartashov A, Lancaster L., Noble PW, Raghu G, Sahn SA, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184:459-466.
13. Richards TJ, Kaminski N, Baribaud F., Flavin S, Brodmerkel C, Horowitz D., Li K, Choi J, Vuga LJ, Lindell KO, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185:67-76.
14. Ley B, Collard HR Risk prediction in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185:6-7.
15. Yang IV, Luna LG, Cotter J, Talbert J., Leach SM, Kidd R, Turner J, Kummer N., Kervitsky D, Brown KK, et al. The peripheral blood transcriptome identifies the presence and extent of disease in idiopathic pulmonary fibrosis. PLoS ONE 2012; 7:e37708.
16. Dilling DF, Gilbert ER, Picken M.M., Eby JM, Love RB, Le Poole IC. A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options. Am J Respir Cell Mol Biol 2012; 46:1-5.
17. McCormack FX, Travis WD, Colby T.V., Henske EP, Moss J. Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med 2012; 186: 1210-1212.
18. Baldi BG, Albuquerque AL, Pimenta S.P., Salge JM, Kairalla RA, Carvalho CR Exercise performance and dynamic hyperinflation in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2012; 186: 341-348.
19. Doyle TJ, Hunninghake GM, Rosas IO Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med 2012; 185:1147-1153.
20. Doyle TJ, Washko GR, Fernandez I.E., Nishino M., Okajima Y, Yamashiro T, Divo M.J., Celli BR, Sciurba FC, Silverman EK, et al. COPDGene Investigators. Interstitial lung abnormalities and reduced exercise capacity. Am J Respir Crit Care Med 2012; 185:756-762.
21. Washko GR, Hunninghake GM, Fernandez I.E., Nishino M., Okajima Y, Yamashiro T, Ross J.C., Estépar RS, Lynch DA, Brehm JM, et al. COPDGene Investigators. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 2011; 364:897-906.
22. Lederer DJ. Secondary prevention of idiopathic pulmonary fibrosis: catching the horse still in the barn. Am J Respir Crit Care Med 2012; 185:697-699.
23. Xu JF, Washko GR, Nakahira K, Hatabu H., Patel AS, Fernandez IE, Nishino M, Okajima Y., Yamashiro T, Ross JC, et al. COPDGene Investigators. Am J Respir Crit Care Med 2012; 185:547-556.
24. Thannickal VJ, Hagood JS Biological insights from clinical trials and networks. Am J Respir Crit Care Med 2012; 185:475-476.
25. Fischer A, Schmid B, Ellinghaus D., Nothnagel M, Gaede KI, Schürmann M, Lipinski S., Rosenstiel P, Zissel G, Höhne K, et al. A novel sarcoidosis risk locus for Europeans on chromosome 11q13.1. Am J Respir Crit Care Med 2012; 186:877-885.
26. van Moorsel C.H., Christiani DC Genetic susceptibility to sarcoidosis, a chronic inflammatory disorder. Am J Respir Crit Care Med 2012; 186:816-818.
27. Adrianto I, Lin CP, Hale J.J., Levin AM, Datta I, Parker R, Adler A., Kelly JA, Kaufman KM, Lessard CJ, et al. Genome-wide association study of African and European Americans implicates multiple shared and ethnic specific loci in sarcoidosis susceptibility. PLoS ONE 2012; 7:e43907.
28. Levin AM, Iannuzzi MC, Montgomery C.G., Trudeau S., Datta I, McKeigue P, Fischer A., Nebel A, Rybicki BA. Association of ANXA11 genetic variation with sarcoidosis in African Americans and European Americans. Genes Immun 2013; 14:13-18.
29. Selman M, Pardo A, King TE Jr. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med 2012; 186:314-324.
30. Walsh SL, Sverzellati N, Devaraj A., Wells AU, Hansell DM Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. Eur Radiol 2012; 22:1672-1679.
31. Takemura T, Akashi T, Kamiya H., Ikushima S, Ando T, Oritsu M., Sawahata M, Ogura T. Pathological differentiation of chronic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis/usual interstitial pneumonia. Histopathology 2012; 61:1026-1035.
32. King TE J.r., Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2013; 378:1949-1961.
33. Tsujino K, Takeda Y, Arai T., Shintani Y, Inagaki R, Saiga H., Iwasaki T, Tetsumoto S, Jin Y, Ihara S, et al. Tetraspanin CD151 protects against pulmonary fibrosis by maintaining epithelial integrity. Am J Respir Crit Care Med 2012; 186:170-180.
34. Selman M, Pardo A. Alveolar epithelial cell disintegrity and subsequent activation: a key process in pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186:119-121.
35. Young LR, Gulleman PM, Bridges J.P., Weaver TE, Deutsch GH, Blackwell TS, McCormack FX The alveolar epithelium determines susceptibility to lung fibrosis in Hermansky-Pudlak syndrome. Am J Respir Crit Care Med 2012; 186:1014-1024.
36. Mahavadi P, Guenther A, Gochuico BR Hermansky-Pudlak syndrome interstitial pneumonia: it's the epithelium, stupid! Am J Respir Crit Care Med 2012; 186:939-940.
37. Yu G, Kovkarova-Naumovski E, Jara P., Parwani A, Kass D, Ruiz V., Lopez-Otín C, Rosas IO, Gibson KF, Cabrera S, et al. Matrix metalloproteinase-19 is a key regulator of lung fibrosis in mice and humans. Am J Respir Crit Care Med 2012; 186:752-762.
38. Walker NM, Badri LN, Wadhwa A, Wettlaufer S., Peters-Golden M, Lama VN Prostaglandin E2 as an inhibitory modulator of fibrogenesis in human lung allografts. Am J Respir Crit Care Med 2012; 185:77-84.
39. Crestani B. Bronchoalveolar lavage brings mesenchymal stem cells to the light. Am J Respir Crit Care Med 2012; 185:7-8.
40. Mackinnon AC, Gibbons MA, Farnworth S.L., Leffler H., Nilsson UJ, Delaine T, Simpson AJ, Forbes SJ, Hirani N, Gauldie J., et al. Regulation of transforming growth factor-b1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 2012; 185:537-546.
41. Königshoff M., Rojas M. Galectin-3: the bridge over troubled waters. Am J Respir Crit Care Med 2012; 185:473-475.
42. Kottmann RM, Kulkarni AA, Smolnycki K.A., Lyda E., Dahanayake T, Salibi R, Honnons S., Jones C, Isern NG, Hu JZ, et al. Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-b. Am J Respir Crit Care Med 2012; 186:740-751.
43. Tuder RM, Lara AR, Thannickal VJ Lactate, a novel trigger of transforming growth factor-b activation in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186:701-703.
44. Zhou Y, Lee JY, Lee C.M., Cho WK, Kang MJ, Koff JL, Yoon PO, Chae J, Park H.O., Elias JA, et al. Amphiregulin, an epidermal growth factor receptor ligand, plays an essential role in the pathogenesis of transforming growth factor-b-induced pulmonary fibrosis. J Biol Chem 2012; 287:41991-42000.
45. Tschumperlin DJ, Jones JC, Senior RM The fibrotic matrix in control: does the extracellular matrix drive progression of idiopathic pulmonary fibrosis? Am J Respir Crit Care Med 2012; 186:814-816.
46. Booth AJ, Hadley R, Cornett A.M., Dreffs AA, Matthes SA, Tsui JL, Weiss K, Horowitz J.C., Fiore VF, Barker TH, et al. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med 2012; 186:866-876.
47. Aono Y, Ledford JG, Mukherjee S, Ogawa H., Nishioka Y, Sone S, Beers M.F., Noble PW, Wright JR. Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury. Am J Respir Crit Care Med 2012; 185:525-536.
48. Scotton CJ, Chambers RC Innate immunity in lung fibrosis: a therapeutic role for surfactant protein D? Am J Respir Crit Care Med 2012; 185:471-473.
49. Maitra M, Cano CA, Garcia CK Mutant surfactant A2 proteins associated with familial pulmonary fibrosis and lung cancer induce TGF-b1 secretion. Proc Natl Acad Sci USA 2012; 109:21064-21069.
50. Sanders YY, Ambalavanan N, Halloran B., Zhang X, Liu H, Crossman D.K., Bray M., Zhang K, Thannickal VJ, Hagood JS. Altered DNA methylation profile in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186:525-535.
51. Rabinovich EI, Selman M, Kaminski N. Epigenomics of idiopathic pulmonary fibrosis: evaluating the first steps. Am J Respir Crit Care Med 2012; 186:473-475.
52. Rabinovich EI, Kapetanaki MG, Steinfeld I, Gibson K.F., Pandit KV, Yu G, Yakhini Z, Kaminski N. Global methylation patterns in idiopathic pulmonary fibrosis. PLoS ONE 2012; 7:e33770.
53. Cisneros J, Hagood J, Checa M., Ortiz-Quintero B, Negreros M, Herrera I., Ramos C, Pardo A, Selman M. Hypermethylation-mediated silencing of p14(ARF) in fibroblasts from idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012; 303:L295-L303.
54. Robinson CM, Neary R, Levendale A., Watson CJ, Baugh JA Hypoxia-induced DNA hypermethylation in human pulmonary fibroblasts is associated with Thy-1 promoter methylation and the development of a pro-fibrotic phenotype. Respir Res 2012; 13:74.
55. Hogaboam CM, Murray L, Martinez FJ Epigenetic mechanisms through which Toll-like receptor-9 drives idiopathic pulmonary fibrosis progression. Proc Am Thorac Soc 2012; 9:172-176.
56. Milosevic J, Pandit K, Magister M., Rabinovich E, Ellwanger DC, Yu G, Vuga L.J., Weksler B., Benos PV, Gibson KF, et al. Profibrotic role of miR-154 in pulmonary fibrosis. Am J Respir Cell Mol Biol 2012; 47:879-887.
57. Yang S, Banerjee S, de Freitas A, Sanders YY, Ding Q, Matalon S., Thannickal VJ, Abraham E, Liu G. Participation of miR-200 in pulmonary fibrosis. Am J Pathol 2012; 180:484-493.